会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • Negative-Electrode Material And Lithium Secondary Battery Using Same
    • 负电极材料和锂二次电池使用相同
    • US20120064400A1
    • 2012-03-15
    • US13319589
    • 2010-05-13
    • Kazunori TakadaBui Thi HangTsuyoshi Ohnishi
    • Kazunori TakadaBui Thi HangTsuyoshi Ohnishi
    • H01M4/02B05D5/12
    • H01M10/0562H01M4/0421H01M4/136H01M4/1397H01M4/624H01M10/052Y02T10/7011
    • An embodiment of the present application aims at providing a material which repeatedly undergoes a conversion reaction and an alloying reaction to have an improved coulombic efficiency in a first cycle of the repeating, and thereby allowing the material to serve as a high-electrical capacity negative electrode of a lithium secondary battery. In order to attain the object, a negative-electrode material is made by mixed dispersion of (i) nanoparticles of an electrical conducting material having electronic conduction and (ii) nanoparticles of an electrode active material which is reducible to a simple substance which undergoes an alloying reaction with lithium. The electrical conducting material is a sulfide having electronic conduction, and the electrode active material is a sulfide of an element which undergoes the alloying reaction with lithium. Further, the element which undergoes the alloying reaction with lithium is silicon.
    • 本申请的一个实施方案旨在提供重复进行转化反应和合金化反应的材料,以在重复的第一循环中具有改善的库仑效率,从而允许该材料用作高电容负极 的锂二次电池。 为了达到上述目的,通过(i)具有电子传导性的导电材料的纳米颗粒和(ii)电极活性材料的纳米颗粒的混合分散体制成负极材料,所述纳米颗粒可还原成经历 与锂的合金化反应。 导电材料是具有电子导电性的硫化物,并且电极活性材料是与锂进行合金化反应的元素的硫化物。 此外,与锂进行合金化反应的元素是硅。
    • 9. 发明授权
    • Preparation and uses of new prostaglandin derivatives which protect cell
membranes against ischemic, physical, chemical, and biological injuries
    • 新的前列腺素衍生物的制备和用途,其保护细胞膜免受缺血,物理,化学和生物损伤
    • US4840968A
    • 1989-06-20
    • US147839
    • 1988-01-25
    • Tsuyoshi Ohnishi
    • Tsuyoshi Ohnishi
    • C07C405/00
    • C07C405/00
    • The invention provides novel compounds which can protect (i) organs, such as the brain, spinal cord, heart, lung, liver, kidney, stomach, duodenum and blood vessels, (ii) skin cells, and (iii) circulating cells such as red blood cells and white blood cells from ischemic, physical, chemical and biological injuries either by pre-administation or post-administration. The compounds can also protect red blood cells from malarial parasites. The compounds are synthesized from prostaglandin A.sub.1 or E.sub.1 first by alkaline treatment to form free-acid molecules, and then by converting them to hydrophobic ester-form compounds. Comparing with free-acid compounds, the ester-form compounds have the following advantageous features: (a) Unlike free-acids, they do not form insoluble micelles with calcium in the blood stream; (b) they are more soluble in lipids than free-acids, thus they are more easily incorporated into cells; (c) they are more stable than free-acids; (d) they are hydrolyzed by endogeneous esterases upon entering the cells, thereby forming the free-acid molecules within the cells. This causes continuous accumulation within the cells. This causes continuous accumulation of free-acid molecules within the cells, and makes their concentration higher than the external concentration of original ester-form compounds. Thus, they can manifest high efficacy; (e) the free-acid molecules thus accumulated within the cells protect the cell membranes by chelating calcium ions, by inhibiting membrane-degradating enzymes and by inhibiting undesirable enzymic reactions within the cell. These compounds can be administered orally, subcutaneously, intramuscularly, intravenously or topically. These compounds can also be used to protect organs during transplant surgery by administering to the donor before removal of the organ and by administering to the receipient after transplantation.